CV DEATH HAS A NEW OPPONENT
CV DEATH HAS A NEW OPPONENT

Advantages of Empagliflozin (JARDIANCE) in HFrEF

Document ID: PC-PH-103621

06/12/2022

Author: Boehringer Ingelheim

Related content

 
PC-PH-103621
Production date: December 2022